CollPlant Biotechnologies (CLGN)

• Market cap: $39.1M
• 1 day: -7.34%
• 5 days: -7.59%
• 1 month: -19.39%
• 3 months: -26.03%
• 6 months: -29.98%
• Year to date: -43.64%
• 1 year: -35.05%
• 5 years: -81.12%
• 10 years: -81.12%

About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Employees: 73

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

2.21% less ownership

Funds ownership: 12.99% [Q2] → 10.78% (-2.21%) [Q3]

8% less capital invested

Capital invested by funds: $7.39M [Q2] → $6.79M (-$599K) [Q3]

19% less funds holding

Funds holding: 16 [Q2] → 13 (-3) [Q3]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 223% upside
• Avg. target: $12.50 267% upside
• High target: $14 311% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	223% upside $11	Buy Reiterated	29 Nov 2024
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	311% upside $14	Buy Maintained	27 Nov 2024